Effects of Stock Type and Fall Fertilization on Survival of Longleaf Pine Seedlings Planted in Lignite Minespoil

One-year-old longleaf pine (Pinus palustris Mill.) seedlings were hand-planted in January 1996 on an east Texas minespoil site. Effects of two seedling stock types and four levels of preplanting fall fertilization on seedling survival were evaluated. Fertilizer treatments consisting of a single application of ammonium nitrate (73 kilograms per hectare N), phosphorus (81 kilograms per hectare P), diammonium phosphate (73 kilograms per hectare N, 81 kilograms per hectare P), or control (no fertilizer) were applied to bare-root and container seedlings in November 1995. Root growth potential, the ability of a seedling to initiate and elongate new roots when placed into a favorable environment, was measured at time of planting. Field survival was surveyed monthly beginning in April 1996. Data were examined using analysis of variance. Container seedlings had significantly higher root growth potential and survival than bare-root. Fertilizer treatment effects, while not significant, tended to decrease both root growth potential and early survival for bare-root seedlings, and to increase root growth potential and decrease survival for container seedlings. Drought conditions during the 1996 growing season probably had a negative effect on survival of both bare-root and container seedlings. Only 2 percent of bare-root and 56 percent of container seedlings survived through the growing season, suggesting that only container stock should be used for reforestation of longleaf on minespoil sites. However, in years with normal precipitation, stock type effects on survival may not be significant and planting bare-root seedlings may be a viable option

Xylem and soil CO2 fluxes in a Quercus pyrenaica Willd. coppice: Root respiration increases with clonal size

Xylem and soil CO2 fluxes in coppiced oak forests increase with clonal size suggesting larger expenditures of energy for root respiration. An imbalance between root demand and shoot production of carbohydrates may contribute to the degradation of abandoned coppices

A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis:a protocol for the CLEAR clinical trial

Background: Current guidelines for the management of bronchiectasis (BE) highlight the lack of evidence to recommend mucoactive agents, such as hypertonic saline (HTS) and carbocisteine, to aid sputum removal as part of standard care. We hypothesise that mucoactive agents (HTS or carbocisteine, or a combination) are effective in reducing exacerbations over a 52-week period, compared to usual care. Methods: This is a 52-week, 2 × 2 factorial, randomized, open-label trial to determine the clinical effectiveness and cost effectiveness of HTS 6% and carbocisteine for airway clearance versus usual care-the Clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care (CLEAR) trial. Patients will be randomised to (1) standard care and twice-daily nebulised HTS (6%), (2) standard care and carbocisteine (750 mg three times per day until visit 3, reducing to 750 mg twice per day), (3) standard care and combination of twice-daily nebulised HTS and carbocisteine, or (4) standard care. The primary outcome is the mean number of exacerbations over 52 weeks. Key inclusion criteria are as follows: Adults with a diagnosis of BE on computed tomography, BE as the primary respiratory diagnosis, and two or more pulmonary exacerbations in the last year requiring antibiotics and production of daily sputum. Discussion: This trial's pragmatic research design avoids the significant costs associated with double-blind trials whilst optimising rigour in other areas of trial delivery. The CLEAR trial will provide evidence as to whether HTS, carbocisteine or both are effective and cost effective for patients with BE. Trial registration: EudraCT number: 2017-000664-14 (first entered in the database on 20 October 2017). ISRCTN.com, ISRCTN89040295. Registered on 6 July/2018. Funder: National Institute for Health Research, Health Technology Assessment Programme (15/100/01). Sponsor: Belfast Health and Social Care Trust. Ethics Reference Number: 17/NE/0339. Protocol version: V3.0 Final_14052018

Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/136359/1/ijc30600_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/136359/2/ijc30600.pd